Home » Newsletters » BioWorld Science

BioWorld Science

April 29, 2019

View Archived Issues

Clotbuster's clot-busting may be beside the point

Preclinical results of a systemic mRNA therapy for Fabry disease

Discovery of novel selective hematopoietic prostaglandin D synthase inhibitors

Takeda's TAK-981 inhibits SUMOylation in vivo, heads to phase I

Sun Yat-sen University describes mesenchymal stem cells overexpressing CCR2

AEBi Accelerated Evolution Biotechnologies presents cytotoxic peptides

New NLRP3 inflammasome inhibitors patented by Inflazome

Theralase initiates phase II study of TLD-1433 in nonmuscle-invasive bladder cancer

Prevail Therapeutics describes glucocerebrosidase constructs

New regenerative therapy developed for Strep pneumonia

Rapid diagnosis of rare diseases

KIAA0125 found to be a diagnostic marker in ameloblastoma

Preclinical characterization of a novel oHSV-expressing bispecific antibody, ONCR-148

ARHGEF2 as a novel prognosis marker in pancreatic cancer

Novel animal model of advanced NASH mimics main characteristics of human disease

FDA approves intravenous Benlysta for pediatric SLE

FDA approves Praluent to reduce risk of heart attack, stroke and unstable angina

First-in-human trial scheduled for TGF-beta receptor type-1 inhibitor GFH-018

Guangdong Zhongsheng Pharmaceutical completes phase I study of ZSP-1273

Novo Nordisk reports phase III results with Victoza in pediatric type 2 diabetes

AstraZeneca and Ionis Pharmaceuticals collaborate on antisense oligonucleotide targeting FOXP3

4D Pharma offers update on development of MRx-0518

European Commission approves Zynquista for type 1 diabetes

Conditional marketing authorization granted in E.U. for Ondexxya to reverse factor Xa inhibitors

Maruishi reports results from Japanese phase III study of Traumakine in ARDS

ObsEva reports follow-up data from phase III IMPLANT2 study of nolasiban

Omeicos doses first patient in phase II study of OMT-28 for atrial fibrillation